

Late Stage Pipeline – Pharma & Vaccines

Phase III			Registration
LixiLan lixisenatide + insulin glargine Fixed-Ratio / Type 2 diabetes	patisiran (ALN-TTR02) N siRNA inhibitor targeting TTR Familial amyloid polyneuropathy	Clostridium difficile Toxoid vaccine	Toujeo® (U300) N insulin glargine Type 1+2 diabetes, U.S., EU
Lyxumia® (lixisenatide) N GLP-1 agonist Type 2 diabetes, U.S.	revusiran (ALN-TTRsc) N siRNA inhibitor targeting TTR Familial amyloid cardiomyopathy	Rotavirus Live attenuated tetravalent Rotavirus oral vaccine	Praluent™ (alirocumab) N Anti-PCSK-9 mAb Hypercholesterolemia, U.S., EU
SAR342434 N insulin lispro Type 1+2 diabetes	Kynamro® (mipomersen) Apolipoprotein B-100 antisense Severe HeFH, U.S.	VaxiGrip® QIV IM Quadrivalent inactivated influenza vaccine	Dengue Mild-to-severe dengue fever vaccine
sarilumab N Anti-IL-6R mAb Rheumatoid arthritis	Jevtana® (cabazitaxel) Metastatic prostate cancer (1L)		PR5i DTP-HepB-Polio-Hib Pediatric hexavalent vaccine, U.S., EU
dupilumab N Anti-IL4Rα mAb Atopic dermatitis	SYNVISC-ONE® Medical device Pain in hip OA		QuadraceI® Diphtheria, tetanus, pertussis & polio vaccine; 4-6 y of age

N New Molecular Entity

- Oncology
- Diabetes Solutions
- Rare Diseases
- Biosurgery

- Immune Mediated Diseases
- Infectious Diseases
- Cardiovascular / Renal Diseases

- Vaccines
- Ophthalmology
- Age Related Degenerative Diseases